JPWO2020037203A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020037203A5 JPWO2020037203A5 JP2021507927A JP2021507927A JPWO2020037203A5 JP WO2020037203 A5 JPWO2020037203 A5 JP WO2020037203A5 JP 2021507927 A JP2021507927 A JP 2021507927A JP 2021507927 A JP2021507927 A JP 2021507927A JP WO2020037203 A5 JPWO2020037203 A5 JP WO2020037203A5
- Authority
- JP
- Japan
- Prior art keywords
- individual
- genes listed
- score
- pathway activity
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719545P | 2018-08-17 | 2018-08-17 | |
| US62/719,545 | 2018-08-17 | ||
| PCT/US2019/046814 WO2020037203A2 (en) | 2018-08-17 | 2019-08-16 | Diagnostic and therapeutic methods for the treatment of breast cancer |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021533787A JP2021533787A (ja) | 2021-12-09 |
| JP2021533787A5 JP2021533787A5 (https=) | 2022-08-18 |
| JPWO2020037203A5 true JPWO2020037203A5 (https=) | 2022-08-18 |
| JP7571006B2 JP7571006B2 (ja) | 2024-10-22 |
Family
ID=67809706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507927A Active JP7571006B2 (ja) | 2018-08-17 | 2019-08-16 | 乳がんの処置のための診断的および治療的方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11081236B2 (https=) |
| EP (1) | EP3837548A2 (https=) |
| JP (1) | JP7571006B2 (https=) |
| KR (1) | KR102754524B1 (https=) |
| CN (1) | CN113490850B (https=) |
| AU (1) | AU2019321588B2 (https=) |
| CA (1) | CA3109090A1 (https=) |
| IL (1) | IL280707B2 (https=) |
| MX (1) | MX2021001857A (https=) |
| TW (1) | TW202022124A (https=) |
| WO (1) | WO2020037203A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180098963A1 (en) * | 2016-10-11 | 2018-04-12 | Duke University | Lasofoxifene treatment of breast cancer |
| CA3109090A1 (en) | 2018-08-17 | 2020-02-20 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for the treatment of breast cancer |
| MX2022000279A (es) | 2019-07-07 | 2022-02-03 | Olema Pharmaceuticals Inc | Regimenes de antagonistas del receptor de estrogeno. |
| KR20220113695A (ko) * | 2019-12-09 | 2022-08-16 | 사노피 | 7h-벤조[7]아눌렌-2-카르복실산 유도체의 결정질 형태 |
| CN115175679A (zh) * | 2020-03-06 | 2022-10-11 | 奥列马制药公司 | 治疗雌激素受体相关疾病的方法 |
| TWI800827B (zh) | 2020-05-12 | 2023-05-01 | 美商建南德克公司 | 使用包含gdc-9545及cdk4/6抑制劑之組合療法治療乳癌 |
| CN111893112A (zh) * | 2020-08-12 | 2020-11-06 | 上海尤里卡信息科技有限公司 | 胃癌肿瘤标志物及其应用 |
| CN114105977B (zh) * | 2020-08-28 | 2023-09-01 | 先声再明医药有限公司 | 雌激素受体调节剂化合物及其用途 |
| JP7830464B2 (ja) * | 2020-11-23 | 2026-03-16 | サノフイ | 乳がんにおける内分泌療法のモニタリングに使用するためのｅｒ制御遺伝子のパネル |
| EP4267578A4 (en) | 2020-12-23 | 2024-11-20 | Recurium IP Holdings, LLC | ESTROGEN RECEPTOR MODULATORS |
| WO2022166983A1 (zh) * | 2021-02-08 | 2022-08-11 | 贝达药业股份有限公司 | 杂芳基并哌啶类衍生物及其药物组合物和应用 |
| JP2024506385A (ja) * | 2021-02-16 | 2024-02-13 | ジェネンテック， インコーポレイテッド | Ｇｄｃ－９５４５及びｇｄｃ－００７７を含む併用療法を使用する乳がんの治療 |
| MX2023009374A (es) | 2021-02-16 | 2023-08-16 | Genentech Inc | Tratamiento de cancer de mama mediante el uso de tratamientos conjuntos que comprenden gdc-9545 y abemaciclib o ribociclib. |
| JP2024506347A (ja) | 2021-02-16 | 2024-02-13 | ジェネンテック， インコーポレイテッド | Ｇｄｃ－９５４５およびイパタセルチブを含む併用療法を使用する乳がんの処置 |
| US11919879B2 (en) | 2021-06-16 | 2024-03-05 | Celgene Corporation | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases |
| CN117813288A (zh) * | 2021-07-15 | 2024-04-02 | 西藏海思科制药有限公司 | 芳氨基衍生物雌激素受体调节剂及其用途 |
| WO2023018197A1 (ko) * | 2021-08-09 | 2023-02-16 | 고려대학교 산학협력단 | 자기공명영상과 rna 유전자 정보를 이용한 유방암 관련 정보제공 방법 |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| WO2023091550A1 (en) * | 2021-11-18 | 2023-05-25 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| CN119013252A (zh) * | 2022-04-15 | 2024-11-22 | 赛诺菲 | 取代的6,7-二氢-5h-苯并[7]轮烯衍生物，用于其制备的方法及其治疗用途 |
| WO2023221122A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Salts and solid forms of an estrogen receptor antagonist |
| WO2023221123A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Crystalline forms of an estrogen receptor antagonist |
| WO2024015506A1 (en) * | 2022-07-14 | 2024-01-18 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
| WO2024076633A1 (en) * | 2022-10-05 | 2024-04-11 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
| IL320004A (en) * | 2022-10-05 | 2025-06-01 | Olema Pharmaceuticals Inc | Methods of treating estrogen receptor-mediated disorders |
| WO2025096907A1 (en) * | 2023-11-01 | 2025-05-08 | The Children's Medical Center Corporation | Methods and compositions for immunosuppressant resistant cellular therapies |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| US6638727B1 (en) * | 1999-01-26 | 2003-10-28 | Cytyc Health Corporation | Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
| JP2005512510A (ja) * | 2001-05-16 | 2005-05-12 | ノバルティス アクチエンゲゼルシャフト | 予後および治療標的として乳癌で発現される遺伝子 |
| CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
| BRPI0414553A (pt) * | 2003-09-19 | 2006-11-07 | Arcturus Bioscience Inc | previsão do resultado de tratamento contra o cáncer de mama |
| EP2195467B1 (en) * | 2007-09-06 | 2016-12-14 | bioTheranostics, Inc. | Tumor grading and cancer prognosis in breast cancer |
| HUE033581T2 (hu) | 2010-06-10 | 2017-12-28 | Seragon Pharmaceuticals Inc | Ösztrogén receptor modulátorok és alkalmazásaik |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| SG11201405918XA (en) | 2012-03-20 | 2014-10-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| US9169207B2 (en) * | 2012-03-27 | 2015-10-27 | Incuron, Llc | Curaxins for use in treating carcinogen-induced cancer |
| US10175240B2 (en) * | 2012-08-23 | 2019-01-08 | The Regents Of The University Of Colorado, A Body Corporate | Method for determining breast cancer treatment |
| EP2912033A4 (en) | 2012-10-24 | 2016-09-14 | Univ Illinois | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-MEDIATED ILLNESSES |
| WO2014066692A1 (en) | 2012-10-24 | 2014-05-01 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating estrogen-related medical disorders |
| AU2013368945B2 (en) * | 2012-12-26 | 2020-01-23 | Innosign B.V. | Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions |
| JP2016517420A (ja) | 2013-03-14 | 2016-06-16 | セラゴン ファーマシューティカルズ， インク． | 多環式エストロゲン受容体モジュレーター及びその使用 |
| ES2829912T3 (es) * | 2013-09-11 | 2021-06-02 | Bio Theranostics Inc | Predecir la reaparición de cáncer de mama |
| FI3834824T3 (fi) * | 2014-03-28 | 2025-12-05 | Univ Duke | Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla |
| JP7065610B6 (ja) * | 2014-10-24 | 2022-06-06 | コーニンクレッカ フィリップス エヌ ヴェ | 複数の細胞シグナル伝達経路活性を用いる治療応答の医学的予後及び予測 |
| KR102785474B1 (ko) * | 2014-12-18 | 2025-03-26 | 에프. 호프만-라 로슈 아게 | 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도 |
| US10399939B2 (en) | 2015-11-09 | 2019-09-03 | Genentech, Inc. | Tetrahydronaphthalene estrogen receptor modulators and uses thereof |
| CN109362222B (zh) | 2016-02-05 | 2021-03-19 | 益方生物科技(上海)股份有限公司 | 选择性雌激素受体降解物及其用途 |
| LT3416962T (lt) | 2016-02-15 | 2021-07-12 | Sanofi | 6,7-dihidro-5h-benzo[7]anuleno dariniai kaip estrogenų recepptoriaus moduliatoriai |
| AU2017239348B2 (en) | 2016-03-25 | 2020-03-12 | Luoxin Healthcare Science and Technology Development (Beijing) Ltd. | Substituted-indole compounds as estrogen receptor down-regulators |
| JP7018026B2 (ja) | 2016-06-16 | 2022-02-09 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | ヘテロアリールエストロゲン受容体モジュレーター及びその使用 |
| US20170362228A1 (en) | 2016-06-16 | 2017-12-21 | Genentech, Inc. | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| WO2018019793A1 (en) | 2016-07-25 | 2018-02-01 | Astrazeneca Ab | N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| TWI735681B (zh) | 2016-10-24 | 2021-08-11 | 瑞典商阿斯特捷利康公司 | 化合物 |
| US10774081B2 (en) | 2016-10-28 | 2020-09-15 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Indolo substituted piperidine compound as estrogen receptor down-regulator |
| ES3039455T3 (en) | 2016-11-17 | 2025-10-21 | Sanofi Sa | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof |
| EP3565558B1 (en) | 2017-01-06 | 2023-12-06 | G1 Therapeutics, Inc. | Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer |
| CA3109090A1 (en) | 2018-08-17 | 2020-02-20 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for the treatment of breast cancer |
-
2019
- 2019-08-16 CA CA3109090A patent/CA3109090A1/en active Pending
- 2019-08-16 US US16/542,817 patent/US11081236B2/en active Active
- 2019-08-16 IL IL280707A patent/IL280707B2/en unknown
- 2019-08-16 JP JP2021507927A patent/JP7571006B2/ja active Active
- 2019-08-16 MX MX2021001857A patent/MX2021001857A/es unknown
- 2019-08-16 TW TW108129347A patent/TW202022124A/zh unknown
- 2019-08-16 KR KR1020217007867A patent/KR102754524B1/ko active Active
- 2019-08-16 WO PCT/US2019/046814 patent/WO2020037203A2/en not_active Ceased
- 2019-08-16 CN CN201980067809.7A patent/CN113490850B/zh active Active
- 2019-08-16 EP EP19762044.6A patent/EP3837548A2/en active Pending
- 2019-08-16 AU AU2019321588A patent/AU2019321588B2/en active Active
-
2021
- 2021-06-25 US US17/359,186 patent/US11676731B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020037203A5 (https=) | ||
| JP2021533787A5 (https=) | ||
| AU744134B2 (en) | Use of a drug capable of modulating the regulation of UPC-2 and method for screening for potential drugs against obesity | |
| Du et al. | Comparative analysis of the immune responses in cancer cells irradiated with X-ray, proton and carbon-ion beams | |
| Wu et al. | Identification of TLR downstream pathways in stroke patients | |
| Neznanov et al. | Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications | |
| von der Heyde et al. | Translating GWAS-identified loci for cardiac rhythm and rate using an in vivo image-and CRISPR/Cas9-based approach | |
| CN108135884A (zh) | 用于治疗aml的药物组合物和治疗有此需要的对象中的aml的方法 | |
| Alleyne et al. | Colonic transcriptional response to 1α, 25 (OH) 2 vitamin D3 in African-and European-Americans | |
| Tian et al. | MicroRNA‐4691‐3p inhibits the inflammatory response by targeting STING in human dental pulp cells: A laboratory investigation | |
| Deng et al. | Genome-wide copy number variation association study suggested VPS13B gene for osteoporosis in Caucasians | |
| Fountain et al. | Kv1. 5 potassium channel gene regulation by Sp1 transcription factor and oxidative stress | |
| Duzanic et al. | The interferon response at the intersection of genome integrity and innate immunity | |
| WO2013103512A1 (en) | Systems genetics network regulators as drug targets | |
| CN114767867A (zh) | 一种用于治疗cdk4/6抑制剂耐药后的乳腺癌的药物组合物及其应用 | |
| Santucci et al. | Radiation-induced gadd45 expression correlates with clinical response to radiotherapy of cervical carcinoma | |
| Tan et al. | Expression profile of circular RNAs in myocardial ischemia/reperfusion with and without intermittent hypobaric hypoxia preconditioning | |
| JP2007509604A (ja) | 薬剤誘発下痢の予測のためのバイオマーカー | |
| Thorne | Exploring the combinatorial effects of inflammatory stimuli and glucocorticoids on BIRC3 and BIRC2 expression: Differential regulation and functional investigations | |
| Li et al. | EP16. 03-043 Comprehensive Genomic Profiling of Tumor Mutational Burden-high in Chinese Lung Cancer Patients | |
| Kitano et al. | Treatment outcomes with radium-223 in patients with metastatic castration-resistant prostate cancer with bone metastasis in real-world practice: a multiinstitutional study | |
| TWI836429B (zh) | 一種預測一癌症病患對於干擾素基因的刺激物激動劑的易感性的方法及套組 | |
| Li et al. | Prognostic and therapeutic value of NK1R: Correlation between function in immune infiltration and expression in tumor microenvironment | |
| Yang et al. | 820 m6A mRNA demethylase FTO regulates tumorigenicity and response to anti-PD-1 immunotherapy in melanoma | |
| Williams et al. | 819 Extragenital lichen sclerosus is an immune-related adverse event with nivolumab |